Latest Breaking News On - 2024 february asco plenary series - Page 1 : comparemela.com

Belantamab mafodotin plus bortezomib and dexamethasone improved PFS vs daratumumab plus bortezomib and dexamethasone in relapsed/refractory myeloma.

United statesRoche genentechRachid bazAbbvie genentechInternational staging systemMoffitt cancer centerRevised international staging systemBelantamab mafodotinMultiple myelomaPhase 3 dreamm 7 trial2024 february asco plenary seriesMaria victoria mateosHospital universitario de salamanca